Solasia PharmaSolasia Pharma K.K.4597東証グロース医薬品FY ending Dec 2023, consolidated, IFRS

What does Solasia Pharma do with its cash?

How cash from operations was spent on investment, dividends, buybacks and more.

Figures for this period are incomplete, so the chart cannot be drawn.

Cash flow ratios

Cash conversion, investment and shareholder payments calculated from disclosed figures.

Net income-¥1.11B

Operating cash flow-¥359M

Nonpositive profit and free cash flow are omitted as ratio denominators. Amounts use the period's reported currency.

Operating cash flow-¥359M

Net income-¥1.11B

Operating cash flow is the cash the core business actually brought in, including changes in receivables and inventory.
Free cash flow = operating cash flow − capital expenditure: a gauge of cash available for other uses.
Large "borrowing" or "cash drawdown" flows mean the company spent more than it generated that year.

Show source documents (4)

EDINET (FSA Japan)
有価証券報告書－第18期(2025/01/01－2025/12/31)
ID S100XT682026-03-24Open
EDINET (FSA Japan)
有価証券報告書－第15期(2022/01/01－2022/12/31)
ID S100QFP52023-03-23Open
EDINET (FSA Japan)
有価証券報告書－第14期(令和3年1月1日－令和3年12月31日)
ID S100NQ7L2022-03-24Open
EDINET (FSA Japan)
有価証券報告書－第13期(令和2年1月1日－令和2年12月31日)
ID S100L2ET2021-03-29Open

Extracted from XBRL: 10 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.